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Changes in thrombin generation and D-dimer
concentrations in women injecting enoxaparin
during pregnancy and the puerperium
Jignesh P Patel1,2*, Raj K Patel1, Lara N Roberts1, Michael S Marsh3, Bruce Green4, J Graham Davies2
and Roopen Arya1
Abstract
Background: It is well accepted that the gravid state is hypercoagulable and a significant cause of both maternal
morbidity and mortality in the Western world. Although thrombin generation is reported to be increased in
pregnant women, uncertainty exists on the pattern of thrombin generation change during this time. The aim of
this study is to describe thrombin generation changes and D-dimer concentrations in women injecting enoxaparin
during pregnancy the postnatal period.
Methods: One hundred and twenty-three women injecting enoxaparin had their thrombin generation, as
measured by Calibrated Automated Thombinography (CAT), repeatedly assayed during pregnancy, once in each
trimester, at delivery and 8 weeks post-partum. Furthermore, to understand the impact enoxaparin has on D-dimer
concentrations during pregnancy, D-dimer concentrations were measured monthly in the recruited women.
Results: Thrombin generation was found to increase in the first trimester (mean endogenous thrombin potential
(ETP): 1391 nmol/L.min), further increasing during the second trimester (mean ETP: 1757 nmol/L.min), after which it
plateaued through to delivery, where it peaked (mean ETP: 1857 nmol/L.min) and then fell back at 8 weeks
post-partum (ETP: 1293 nmol/L.min). In contrast D-dimer concentrations increased exponentially during the
antenatal period, despite the enoxaparin prescription.
Conclusion: Our results provide further evidence on alterations of thrombin generation during pregnancy and the
postnatal period.
Keywords: Blood coagulation, D-dimers, Enoxaparin, Postpartum period, Pregnancy, Thrombin generation, Venous
thromboembolism
Background
Global coagulation assays, such as the thrombin gener-
ation assay, explore the initiation, propagation and ter-
mination phases of coagulation [1], and so can detect an
underlying prothrombotic state. Studies have demon-
strated the utility of the thrombin generation assay in
identifying the prothrombotic states seen with increasing
age [2], in the obese [3], those with thrombophilia [4],
users of oral contraception and hormone replacement
therapy [5,6] and in those of African-Caribbean origin
[7]. Only a small number of studies have explored
thrombin generation during pregnancy [8-12]. Whilst
the results of these studies demonstrate a hypercoagulable
state, the pattern of thrombin generation changes during
pregnancy has provided conflicting results. Knowing how
thrombin generation is altered during the gravid period is
important, as it could help define the periods of greatest
risk and ultimately inform when and how interventions
such as low molecular weight heparin (LMWH) are
prescribed.
In contrast to the global thrombin generation assay,
plasma concentrations of D-dimers represent a sensitive
marker of active coagulation and subsequent fibrinolysis.
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Observational studies in the pregnant population have
demonstrated D-dimer concentrations to increase in line
with gestation [13-18]. Some studies have also demon-
strated this to be the case when pregnant women con-
currently inject prophylactic doses of LMWH [19,20].
The aim of this study was to investigate how thrombin
generation and D-dimer concentrations were altered in
pregnant women injecting enoxaparin during pregnancy
and the postnatal period.
Methods
Study setting
King’s College Hospital (Denmark Hill site) is a 900-bed
tertiary care hospital, with around 5,400 babies delivered
each year, including 1,500 caesarean sections. Nulliparous
and multiparous women prescribed antenatal enoxaparin
were eligible for entry to the study. Women who did not
wish to participate or were unlikely to comply with
directions, those with impaired renal function and
those <18 years of age were excluded. Following in-
formed written consent, subjects attended the throm-
bophilia clinic monthly during their pregnancy for
ongoing monitoring, as well as drawing blood samples
for determination of renal and liver function, full blood
count, and D-dimer concentrations. Once in each tri-
mester, women had additional blood drawn for the assess-
ment of thrombin generation. Samples for assessment of
D-dimer and thrombin generation samples were also
drawn at the time of delivery and at ≥8 weeks post-
partum; the latter sample providing a baseline thrombin
generation and D-dimer concentration for subjects, act-
ing as their own control.
Sample collection and plasma preparation: D-dimers
Samples were obtained through antecubital venepunc-
ture using a butterfly Terumo® Surflo® winged infusion
set (21G × ¾”, 0.8 × 19 mm UTW tubing, REF: SV-
21BL, Terumo Europe N.V., Belgium). For determination
of D-dimer, 2.7 mL blood sample was collected in
0.109 M (3.2% trisodium citrate) Becton-Dickinson
Vacutainer®, centrifuged at 2500 g for 7 minutes on a
Rotina 38 R centrifuge (Hettich Zentrifugen), within
1 hour of collection. The resultant plasma was analysed
using the STA-Liatest® D-DI kit (immune-turbidimetric
assay of D-dimer (Diagnostica Stago, France)). Analysis
was conducted using the STA-R evolution (Diagnostica
Stago) analyser.
Sample collection and plasma preparation: thrombin
generation
Samples were obtained through antecubital venepucture
using the aforementioned infusion set, without the use
of a vacuum and with minimal suction into a 20 ml syr-
inge, with the first 5 ml of blood drawn discarded. The
blood was then transferred to 0.109 M (3.2% trisodium
citrate) Becton-Dickinson Vacutainer®. Platelet poor
plasma (PPP) was obtained by centrifugation at 4750 g
for 10 minutes at room temperature. The supernatant
was decanted into a polypropylene tube and centrifuga-
tion repeated. The plasma was decanted into a plastic
tube, capped and immediately frozen. This procedure
was performed within 60 minutes of venepuncture. The
samples were stored at −35°C and analysed using cali-
brated automated thrombinography (CAT), as developed
by Hemker [21].
Calibrated automated thrombinography
Thrombin generation was measured with the thrombi-
noscope assay (Thrombinoscope BV, The Netherlands),
according to the manufacturer’s instructions, as has pre-
viously been described by our group [6,7,22]. Concentra-
tions of tissue factor and phospholipid used in the
experiments were 5 pmol/L and 4 μmol/L, respectively.
Five thrombin generation parameters were computed:
lag time, time to peak, peak height, start-tail and en-
dogenous thrombin potential (ETP).
Intra- and inter-assay variability was assessed using
plasma from a healthy control (male subject, aged 36–37
years). This volunteer was bled every eight weeks from
the 16th April 2010 to the 24th January 2012. Eight
plasma samples were obtained from the volunteer on
each occasion and one sample was run in each thrombin
generation experiment, from the 20th April 2010 (exp
17) to the 21st February 2012 (exp 125). For the primary
thrombin generation parameters, lag-time, ETP, peak
height, time to peak and start tail, the following coeffi-
cients of variation (%) were obtained: 4.5, 1.6, 3.9, 4.0,
2.1 for intra-assay variation and 7.6, 11.8, 13.7, 7.5 and
5.1 for inter-assay variation.
Statistical analysis
Data was grouped into five time points: first, second and
third trimester, within a week of delivery and ≥8 weeks
post-partum.
Continuous variables are presented as means and
standard deviations or median and inter-quartile ranges
for normally and non-normally distributed variables re-
spectively. For thrombin generation, differences in the
means of variables were compared between the five time
points, using the repeated measures ANOVA with a
Greenhouse-Geisser correction. Post-hoc analysis was
conducted using Bonferroni correction. For D-dimer
concentrations, the Friedmans mean rank test was used
to assess if statistically significant differences existed be-
tween the different time-points, with the Wilcoxon pair
test used to assess significance between specific pairs of
study time points.
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As the Caucasian and African-Caribbean ethnic groups
comprised the majority of the subjects recruited, differ-
ences in the thrombin generation and D-dimers results at
each of the time points were compared for women
injecting prophylactic doses of enoxaparin, using the
independent t-test for thrombin generation and the
Mann–Whitney U independent rank-sum test for D-dimer
concentrations.
Further, to assess the impact of enoxaparin dose on
the thrombin generation parameters and D-dimer con-
centrations, women were grouped into those injecting
treatment doses and those injecting prophylactic doses.
Descriptive statistics was used to report these results.
Statistical significance was considered at the 0.05 α
level. Analysis was performed using SPSS version 18.0
(SPSS Inc., Chicago, Ilinois, USA).
The study received ethical approval from the Isle of
White, Portsmouth and South East Hampshire Ethics
Committee (REC reference: 09/H0501/57).
Results
Study participants and pregnancy outcomes
One hundred and nineteen patients had 123 pregnancies
(4 women had two pregnancies during the study period).
Five (4%) of the 123 pregnancies were twin pregnancies.
The mean age of the recruited cohort was 33.11 years
(range 18–46), and for 26 women, the index pregnancy
was their first. A significant number of women recruited
were obese class I-III (27 women (22%)). Table 1 sum-
marises demographic information.
The range of enoxaparin doses prescribed for the sub-
jects recruited are presented in Additional file 1: Table S1.
Furthermore, details on the 19 women prescribed treat-
ment doses of enoxaparin (9 women managed for ante-
natal VTE and the 10 women switched from long-term
warfarin during pregnancy) are presented in Additional
file 2: Table S2 and Additional file 3: TableS3 respectively.
Pregnancy outcomes
Eight of the 123 pregnancies miscarried; 5 women (4.06%)
had first trimester miscarriages and 2 women (1.62%) had
second trimester miscarriages. The remaining patient had
a still birth at 39 weeks gestation; One hundred and four-
teen patients had 119 live births (delivery information on
one woman was not available, as she emigrated prior to
delivery). Table 2 presents delivery information on the
study cohort.
Thrombin generation
The 123 subjects provided 498 individual thrombin gen-
eration profiles; 414 (83%) of the profiles were drawn
from women prescribed prophylactic doses of enoxa-
parin with the remaining 84 profiles from women pre-
scribed treatment doses.
Table 1 Demographic information on the recruited
subjects and the indication for the enoxaparin prescription
Demographic Number N = 123 (%)
Ethnicity
Caucasian 66 (54)
African-Caribbean 37 (30)
Asian 9 (7)
Other 11 (9)
Primi gravid 26 (21)
Body mass index (kg/m2)
Underweight (<18.5) 2 (2)
Normal (18.5-24.9) 62 (50)
Overweight (25–29.9) 32 (26)
Obese Class I (30–34.9) 7 (6)
Obese Class II (35–39.9) 4 (3)
Obese Class III (≥40) 16 (13)
Indication for antenatal enoxaparin
Prophylaxis of VTE 83 (68)
Treatment of VTE 9 (7)
Antiphospholipid syndrome 9 (7)
Patients converting from long term warfarin 10 (8)
Other* 12 (10)
*7 patients with recurrent miscarriage in the absence of APLS, 1 patient with a
history of retinal artery occlusion, 1 patient with a suspected patent foramen
ovale, 1 patient with a history of a stillbirth – histology findings of the
placenta reported a perivillous fibrin deposition, placental ageing and
dysmaturity, 1 patient with a history of intrauterine growth retardation and
abruption, 1 patient with a history of intrauterine growth retardation and
pregnancy induced hypertension.
Table 2 Delivery outcomes in the recruited subjects
Study population
N = 114 (%)
Gestation delivered (weeks) 38.8
Blood loss recorded at delivery (ml) 433.95
Delivery Method n (%)
Vaginal 61 (54)
LSCS (elective) 23 (20)
LSCS (emergency) 20 (17)
Ventouse 6 (5)
Forceps 4 (4)
Twin pregnancies 5 (4)
Gender
Boy 62 (52)
Girl 57 (48)
Mean Baby weight (g) 3162.43
APGAR score @ 1 minute (mean (min-max)) 8.40 (0–10)
APGAR score @ 5 minutes (mean (min-max)) 9.50 (0–10)
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Overall, the different parameters of the thrombogram
were altered during pregnancy and the postpartum period
(Table 3).
The samples drawn at ≥8 weeks post-delivery provide
an insight into the cohort of women’s baseline thrombin
generation was prior to their pregnancy by which time-
point women had discontinued their anticoagulation
therapy. Using the ≥8 week post-partum values as a ref-
erence point; a rise in ETP is seen over the course of
pregnancy, despite an enoxaparin prescription.
When the thrombin generation results are separated
according to women injecting treatment and prophylac-
tic doses of enoxaparin, a difference in changes are ob-
served between the group of women injecting treatment
doses (84 profiles) and those injecting prophylactic doses
(414 profiles) (Figure 1).
The results demonstrate a dose dependent enoxaparin
effect. The ETP rise over pregnancy for women on treat-
ment doses of enoxaparin is more attenuated, relative to
those women prescribed prophylactic doses, as observed
by differences in peak height. An influence of enoxaparin
on the lag time, time to peak, and start tail is also
observed. Examining the results from the women pre-
scribed prophylactic doses, where all anticoagulant ther-
apy had been discontinued by eight weeks postpartum,
one can see that ETP is already higher by the first trimes-
ter, with a further rise seen during the second trimester,
after which it settles through to delivery, where it peaks.
Eight women prescribed treatment doses of enoxa-
parin, had thrombin generation measurements at all
study time-points. No significant difference in results for
the individual thrombin generation parameters were
found, across these five time-points. This was not the
case, for women prescribed prophylactic doses of enoxa-
parin. In this group, 22 women had thrombin generation
assayed at all study time-points. The following results
were found for each thrombin generation parameter;
Lag-time: significant differences were found between
the time points (F(2.684, 56.261) = 3.732, p < 0.05).
Post-hoc analysis demonstrated significant differences
between the 8 weeks postpartum samples and the
samples drawn in the first, second and third trimester,
where a prolongation of the lag-time was observed.
ETP: the mean ETP concentrations did statistically
differ between the five time points (F(2.312, 48.561) =
9.072, p < 0.05). Post-hoc analysis revealed that specific
differences were between the 8 weeks post-partum time
point and the second and third trimesters and at the
time of delivery, mirroring the result seen for the
cohort of women as a whole.
Peak height: statistically significant differences between
the five time points (F(2.375, 49.877) = 5.209, p = <0.05)
were found. A post-hoc analysis however, was unable to
identify at which time points the differences were.
Time to peak: significant differences were found
(F(2.715, 57.021) = 6.181, p = <0.05). A post-hoc analysis
revealed these differences between the ≥8 weeks
post-partum time point and the first, second and third
trimesters. No significant differences were found
between the samples drawn at delivery and the ≥8 week
post-partum time point.
Start-tail: significant differences were found (F(2.252,
47.291) = 11.953, p = <0.05). A post-hoc analysis
revealed that the specific differences were between
the ≥8 weeks post-partum time point and the other
four time points.
Variation in thrombin generation by ethnicity
The Caucasian and African-Caribbean ethnic groups
represented the majority of ethnic origin groups in the
cohort of women recruited during the course of this
study. The thrombin generation results from these two
groups of women prescribed prophylactic doses of enox-
aparin were also compared (Table 4).
There are significant differences between the two eth-
nic groups for the mean ETP, and peak parameters with
the African-Caribbean group exhibiting higher values for
these relative to their Caucasian counterparts, during
the first and second trimesters.
D-dimers concentrations
Subjects provided 815 separate D-dimer concentrations
from their pregnancies and the puerperium. Table 5 lists
Table 3 Overall thrombin generation results for the cohort of women recruited
TG parameter 1st trimester 2nd trimester 3rd trimester Within 1 week of delivery ≥8 weeks pp
N = 58; n = 44 N = 117; n = 94 N = 132; n = 108 N = 93; n = 93 N = 98; n = 98
Lag time (min) 4.27 (3.81) 3.53 (1.26) 3.88 (2.46) 3.14 (1.32) 3.13 (1.34)
ETP (nmol/L.min) 1391 (795) 1757 (706) 1692 (631) 1857 (633) 1293 (409)
Peak height (nmol/L) 208 (141) 277 (136) 262 (116) 356 (127) 261 (80)
Time to Peak (min) 8.09 (5.18) 7.05 (3.27) 7.36 (3.91) 5.57 (2.83) 5.68 (1.58)
Start tail (min) 27.3 (9.7) 26.4 (6.9) 26.6 (6.8) 24.2 (5.8) 20.6 (2.79)
Mean with sd in brackets presented; pp refers to post-partum. N refers to the number of samples analysed at each time point, n refers to the number of women
providing these samples.
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Figure 1 Box plots illustrating the alterations in the five primary thrombin generation parameters for women injecting prophylactic
(left), treatment (right) doses of enoxaparin during pregnancy and the post-partum period. Trimester 4 refers to delivery and trimester
5 to ≥8 weeks post-partum.
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the pattern of D-dimer concentrations change from each
of the time-points during the study. D-dimer concentra-
tions rose during pregnancy (315 ug/ml), peaking at the
time of delivery (1497 ug/ml), and returning to ‘baseline’
concentrations by 8 weeks postpartum (335 ug/ml).
Although considerable inter-patient variability is ex-
hibited, a clear pattern was observed in line with gesta-
tional age.
Significant differences were found when each study
time-point was compared, except when the first trimester
was compared with the ≥8 weeks post-partum time point.
Women injecting prophylactic versus treatment doses of
enoxaparin: D-dimer concentrations
Table 6 describes the D-dimer concentrations for women
receiving prophylactic doses of enoxaparin (619 concen-
trations), compared to women injecting treatment doses
(196 concentrations).
Twenty-six women injecting prophylactic doses of
enoxaparin had serial D-dimer concentrations measured
consecutively from the first trimester through to ≥8 weeks
post-partum. Statistically significant differences between
the five different time points were found (n = 26, df = 4, p
= <0.05). When the different study time points were com-
pared with one another, significant differences were found
between each study pair, except when the first trimester
was compared with the ≥8 weeks post-partum time point.
Ten women prescribed treatment doses of enoxaparin
had serial D-dimer concentrations consecutively measured
from the first trimester through to ≥8 weeks of delivery.
Statistically significant differences were found between the
five study time points (n = 10, df = 4, p = <0.05); specific-
ally between the second and third trimesters and within a
week of delivery and ≥8 weeks postpartum.
When the Caucasians and African-Caribbean women
injecting prophylactic enoxaparin were compared, no sig-
nificant differences in D-dimer concentrations between
these two groups at all-time points were found (Table 7).
Discussion
To the best of our knowledge, our study is the largest to
date, evaluating thrombin generation in pregnant women
concurrently injecting enoxaparin, involving 498 separate
thrombin generation profiles. This study is one of only
two, to measure thrombin generation repeatedly in the
same women during their pregnancy and the only study to
couple this with thrombin generation measurements at
the time of delivery and 8 weeks post-partum.
The primary aim of this study, was to describe how
thrombin generation, as measured by CAT, was altered
during pregnancy in the cohort of women recruited.
With the 8 weeks post-partum sample acting as a base-
line measurement for the recruited women, we found a
rise in thrombin generation had already occurred in the
first trimester, with a further rise during the second tri-
mester, after which a thrombin generation plateau was
reached through to delivery. At delivery, thrombin gen-
eration peaked and then dropped off by 8 weeks post-
partum. This antenatal pattern of thrombin generation
Table 4 Thrombin generation variation between the Caucasian and African-Caribbean groups
Parameter Ethnicity 1st trimester 2nd trimester 3rd trimester Within one week of delivery ≥ 8 weeks postpartum
N = 34 v 8 N = 67 v 24 N = 75 v 27 N = 45 v 23 N = 47 v 24
Lag time (min) Caucasian 4.11 (1.74) 3.49 (0.83) 3.62 (0.98) 3.03 (1.09) 2.98 (0.57)
A-C 3.27 (0.81) 3.18 (0.74) 3.34 (0.77) 2.73 (0.61) 2.72 (0.51)
ETP (nmol/L.min) Caucasian 1296 (651)* 1806 (557)* 1784 (451) 1944 (578) 1306 (356)
A-C 2126 (754) 2129 (556) 1810 (432) 1911 (540) 1402 (336)
Peak height (nmol/L) Caucasian 193 (124)* 284 (114)* 280 (92) 379 (119) 256 (60)
A-C 323 (146) 356 (112) 301 (96) 367 (91) 286 (63)
tt Peak (min) Caucasian 8.27 (3.6) 6.83 (1.8)* 6.95 (1.9) 5.23 (1.6) 5.65 (0.9)*
A-C 6.61 (2.2) 5.89 (1.3) 6.22 (1.6) 4.88 (1.0) 5.15 (0.9)
Start tail (min) Caucasian 27.94 (7.4) 26.37 (4.3) 26.07 (4.7) 24.29 (3.8) 20.42 (2.7)
A-C 28.10 (3.1) 26.73 (3.9) 25.93 (4.2) 24.40 (4.1) 20.69 (2.8)
*Significance at <0.05 level; A-C refers to the African-Caribbean population, C refers to Caucasian population. N = number of samples in each trimester (Caucasian vs
African-Caribbean). Mean with SD in brackets presented.
Table 5 The overall D-dimer concentration results for the
recruited women
Pregnancy time point N Median (ug/mL) Inter-quartile
range
First trimester (53) 88 315 245-467
Second trimester (103) 240 620 450-970
Third trimester (113) 287 990 690-1550
Within a week of delivery (102) 102 1497 2225-3910
≥ 8 weeks postpartum (98) 98 335 230-482
N represents the number of D-dimer samples at each study time point; numbers
in brackets next to each time-point refer to the number of women providing
samples at that time-point.
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alteration is in agreement with the studies of Rosenkranz
[9] and Dargaud [10]. Other studies provide differing de-
scriptions of thrombin generation changes during preg-
nancy. The first to assess thrombin generation in this
setting was Eichinger and colleagues [23]. In their study,
thrombin generation was measured at fixed time-points
(12, 22, 34 weeks gestation and 3 months post-partum).
They used a tissue factor concentration of 120 pM in
their experiments and report thrombin generation not
to increase during pregnancy, despite evidence of sub-
stantial activation of the fibrinolytic system, through as-
sessment of Fragment 1 + 2, Thrombin-Antithrombin
complex and D-dimer concentrations. It could well be,
that the high tissue factor concentration used in their
study, was masking the true results, that have been re-
ported here and by others. More recently McLean and
colleagues have described thrombin generation in preg-
nant women, by measuring thrombin generation pre-
conception, during early pregnancy (11–15 weeks), during
late pregnancy (30–34 weeks) and again between 6–24
months after delivery [11]. The authors report thrombin
generation increased during pregnancy in line with gesta-
tion. However, the authors did not measure thrombin gen-
eration during the second trimester, so are unable to
conclude categorically from their results whether the in-
crease continues during the second trimester or has
reached a plateau by this time. More recently, Joly and col-
leagues [12] studied 101 women with uncomplicated preg-
nancies, and correlated thrombin generation, as measured
by CAT with fibrinogen and other markers of blood co-
agulation activation. Only one blood sample was collected
for each subject in this study, and they report thrombin
generation to have increased early on during in pregnancy
and then remains stable throughout the remainder of nor-
mal pregnancy. As the same women were not repeatedly
tested, it is difficult to categorically draw this conclusion;
indeed this limitation is apparent in many of the studies
exploring thrombin generation during pregnancy and the
puerperium.
The published research to date appears to agree that
the prothrombotic state of pregnancy can be detected by
the global coagulation assay, thrombin generation, and
that this prothrombotic state is detected from the first
trimester. What remains unclear is how, thrombin gen-
eration is altered through the remainder of pregnancy.
When examining the distribution of VTE through preg-
nancy, some studies report a bimodal distribution of
antenatal VTE with most events in the first and third tri-
mester [24] and others suggest the incidence to increase
non-significantly with increasing gestation [25]. Studies
from the United Kingdom describing the incidence of
VTE during pregnancy in recent years, describe the
Table 6 D-dimer concentrations (ug/ml) for the cohort of women prescribed prophylactic versus treatment doses
Pregnancy time point Prophylactic dose prescribed Treatment dose prescribed
N Median concentration in ug/ml
(inter-quartile range)
N Median concentration in ug/ml
(inter-quartile range)
First trimester 64 335 24 270
(270–487) (230–422)
Second trimester 193 620 47 480
(465–955) (350–1180)
Third trimester 225 1020 62 850
(735–1625) (545–1270)
Within a week of delivery 79 2360 23 1610
(1790–4130) (440–2450)
≥ 8 weeks postpartum 78 365 20 260
(256–525) (220–325)
N represents the number of D-dimer samples at each time point.
Table 7 Median D-dimer concentrations (ug/ml) for the
Caucasian and African-Caribbean ethnic groups of
women prescribed prophylactic doses of enoxaparin
Time point Ethnicity p-value*
Caucasian African –
Caribbean
First Trimester 340 335 U = 247, p = 0.925
(267–512) (302–430)
Second Trimester 600 665 U = 2709, p = 0.225
(457–865) (492–992)
Third Trimester 1000 1135 U = 3541, p = 0.071
(715–1540) (877–1687)
Within a week
of delivery
2400 2350 U = 505, p = 0.760
(1690–4250) (1760–4610)
≥ 8 weeks
post-partum
365 350 U = 504, p = 0.750
(230–505) (300–490)
Median (interquartile range) D-dimer concentrations presented; *Mann–Whitney
U independent rank-sum test.
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incidence to increase with gestation; Voke and colleagues
study of antenatal VTE, reported 31 women presenting in
the first trimester, 37 during the second trimester and 58
during the third trimester [26]. In Knight and colleagues
study of antenatal PE, the median gestational age at diag-
nosis was 28 weeks gestation (range 2–40 weeks) [27].
In order to better understand the relationship between
thrombin generation and the incidence of VTE during
pregnancy, and whether an increased level of thrombin
generation can predict an antenatal VTE event, there is
clearly a need for a study which evaluates thrombin gen-
eration during uncomplicated pregnancy in the same
women at pre-determined pregnancy time points, using
standardised methods and reagents. Such a study, would
not only resolve the uncertainty, it would help provide a
comparator for studies evaluating thrombin generation
changes in women with other antenatal complications,
such as pre-eclampsia.
During our study, the presence of enoxaparin in the
women’s plasma samples will of course be impacting on
the results reported. However, the results suggest only a
small impact of prophylactic enoxaparin on thrombin
generation (as measured by CAT) and that this effect is
unlikely to interfere with the pattern of thrombin gener-
ation being described here. We are relatively confident
of this, in light of what others have also previously re-
ported. Gerotziafas and colleagues [28] assessed the in-
hibition of thrombin generation induced by different
LMWH in-vitro, in platelet rich plasma. They found that
enoxaparin impact on thrombin generation at a concen-
tration less than 0.2 IU/mL was minimal, when com-
pared to unfractionated heparin and tinzaparin, and
anti-Xa concentrations greater than 0.4 IU/mL were re-
quired to induce a significant reduction in the ETP and
peak height. A similar finding has been reported by
Adamidou [29]. Green and colleagues [30] assessed the
thromboprophylatic effect of dalteparin or rivaroxaban
in those patients who had undergone elective hip and
knee replacements. Both these agents are effective in
preventing VTE in this setting. They found patients who
were prescribed dalteparin exhibited a variable thrombin
generation response after surgery, whereas the effects of
rivaroxaban were more consistent. Rivaroxaban was
found to inhibit thrombin generation (as measured by
CAT) more, in relative terms, than dalteparin at 24 hours
post-surgery, even though it is accepted that they are
equally efficacious. The results considered together seem
to suggest that the full impact of prophylactic doses of
enoxaparin are not borne out in the thrombin gener-
ation assay.
D-dimer concentrations
D-dimer concentrations reflect active coagulation and fi-
brinolysis. Our large set of D-dimer results agree with
previously published studies, that D-dimer concentrations
increase exponentially during pregnancy, peaking at the
time of delivery. To date, little work has been published
on how the D-dimer concentrations might be altered in
pregnant women who are concurrently injecting LMWH.
Hoke and colleagues have previously explored this [19]
and assessed 61 women prescribed LMWH thrombopro-
phylaxis throughout pregnancy due to a history of VTE,
hereditary thrombophilia and/or previous pregnancy re-
lated complications. D-dimer concentrations were mea-
sured during their pregnancy, having been prescribed
dalteparin or enoxaparin at a dose range of 4000 to 7500
anti-factor Xa IU daily; commenced following a positive
pregnancy test. The D-dimer concentrations were then
compared with a control group comprising 113 healthy
pregnant women not requiring thromboprophylaxis. The
author’s found that D-dimer concentrations in both sub-
jects and controls increased significantly from the first to
the second trimester, as well as from the second to the
third trimester. The authors also describe the D-dimer
concentrations being significantly higher among subjects
compared with controls. Despite being prescribed prophy-
lactic LMWH, substantial activation of coagulation was
seen during pregnancy in this study, i.e. the prophylactic
doses of LMWH did not dampen down the increase in D-
dimers one might expect to observe. Furthermore, Abou-
Nassar and colleagues [20], as part of the Thrombophilia
in Pregnancy Prophylaxis Study (TIPPS), patients at high
risk of pregnancy complications with confirmed thrombo-
philia were randomised to receive either dalteparin 5000
units daily until 20 weeks gestation, then 5000 units twice
a day until 37 weeks gestation or onset of labour, or no
treatment. Samples for assessment of TAT, prothrombin
fragment 1 + 2, and D-dimer concentrations were
drawn in each trimester. The authors report that the
levels of TAT, prothrombin fragment 1 + 2 and D-
dimer concentrations increased significantly in the dal-
teparin and control group, again illustrating that the
prophylactic LMWH does not impact on the D-dimer
concentrations. The results from our study confer with
the findings from both these studies.
The increase in D-dimer concentrations during preg-
nancy, appear relatively predictable and the utility of
using D-dimer concentrations for the diagnosis of ante-
natal VTE should be explored further, with a view of de-
veloping a normal D-dimer pregnancy reference range,
as has been suggested previously [31-33]. The UK
National Institute for Health Research recently made a
Health Technology Assessment call for researchers to
define the optimal algorithm to diagnose antenatal pul-
monary embolism. The results from this commissioned
research [34] will be eagerly awaited in years to come
and perhaps D-dimer concentrations will form part of
the final diagnostic algorithm recommended.
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Differences in TG and D-dimers between the
African-Caribbean and Caucasian populations
When we compared D-dimer concentrations in women
injecting prophylactic doses of enoxaparin, between the
African-Caribbean and Caucasian populations, no differ-
ences were found. This confirms findings previously re-
ported by our group from a non-pregnant population
[7]. Differences in thrombin generation were found be-
tween the African-Caribbean women compared to the
Caucasian women. These differences were particularly
prominent during the first trimester. The last UK confi-
dential enquiry into maternal deaths report [35] reported
that 3 of the 5 deaths during the first trimester were of
women from an African-Caribbean origin. It could well
be, that significantly higher thrombin generation in these
women, pre-dispose them to VTE during early preg-
nancy more so, than the Caucasian population. In part,
the increased thrombin generation observed may be re-
lated to higher factor VIII levels in the African-Caribbean
population [36], and further work is required comparing
factor VIII concentrations in these two groups of pregnant
women would be useful and might help explain the differ-
ences observed.
Limitations
The results of our work should be considered in the
context of their limitations. Not all women had sequen-
tial thrombin generation and d-dimer concentrations
measured from the first trimester to 8 weeks post-
partum. This was largely due to the women booking
after the first trimester had passed, and then being re-
ferred for haematology input. Furthermore, the sampling
of thrombin generation was done at times when women
were attending for outpatient appointments; ideally sam-
pling would have been completed in defined trimester
‘windows’, to minimise any impact this may have. Finally,
the thrombin generation and ethnicity results were not
controlled for weight, which is known to impact signifi-
cantly on thrombin generation [10]. Future studies spe-
cifically assessing thrombin generation differences in
different ethnic groups, should be mindful to control for
this.
Future work
There is clear need for a study which measures throm-
bin generation longitudally during uncomplicated preg-
nancy. Once the pattern of normal thrombin generation
is known, studies can then begin to evaluate if global coagu-
lation assays can detect other pregnancy co-morbidities,
e.g. pre-eclampsia or intrauterine growth restriction.
Given the differences in TG between the African and
Caucasian population, a study formally evaluating TG
differences between these two groups would be of value,
particularly since the African-Caribbean women represent
a significant proportion of women in the last confidential
enquires report.
Conclusion
We found thrombin generation, as measured by CAT, to
have increased by the first trimester, with a further in-
crease by the second trimester, after which thrombin
generation settled through to delivery. D-dimer concentra-
tions in contrast, increased exponentially during the ante-
natal period. Both thrombin generation and D-dimers
return to baseline levels by 8 weeks postpartum. Our work
provides further evidence on the changes of thrombin
generation and D-dimers during pregnancy and the
puerperium.
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